What's Happening?
Exelixis, Inc. has announced results from a subgroup analysis of the CABINET Phase 3 trial, evaluating CABOMETYX® (cabozantinib) versus placebo in patients with advanced neuroendocrine tumors (NET) originating
in the lungs or thymus. The trial showed CABOMETYX reduced the risk of disease progression or death by 81% compared to placebo. The study involved patients with locally advanced or metastatic pancreatic NET (pNET) or extra-pancreatic NET (epNET), with 49 patients having lung or thymic NET. The median progression-free survival was 8.2 months with CABOMETYX versus 2.7 months with placebo. The trial results will be presented at the European Society for Medical Oncology Congress (ESMO) 2025.
Why It's Important?
The positive results from the CABINET trial highlight CABOMETYX as a promising treatment option for patients with advanced lung and thymic NET, addressing a significant unmet need in oncology. The findings reinforce the drug's efficacy in improving progression-free survival, offering hope for patients with limited treatment options. The trial's success may influence regulatory approvals and expand the use of CABOMETYX in treating various NET subtypes, potentially impacting the pharmaceutical industry and patient care standards.
What's Next?
Exelixis plans to continue serving the NET patient community with ongoing trials, including the STELLAR-311 pivotal trial examining zanzalintinib as a potential first-line therapy. The company aims to further explore CABOMETYX's benefits for heterogeneous NET populations and expand its clinical applications. Regulatory bodies may consider the trial results for future approvals, potentially broadening CABOMETYX's market presence.
